Current LHP COVID-19 research

LHP SPARK is more necessary now than ever with the challenges arising in relation to Coronavirus and the effect this is having on the conduct of research across LHP sites. This is a critical time for infection research across the city with a growing number of national studies and new local studies in development. The SPARK team, NHS delivery teams  and our partners (CRN NWC, LCTC) continue to work collaboratively, at pace, to set up and recruit to COVID-19 research studies.

As of May 27th 2288 patient have been recruited by LHP members into COVID-19 research and 576 into national COVID service evaluations

Read more about the current portfolio below:

The NIHR have established three Urgent Public Health (UPH) platform trials which are vital to the UK COVID-19 research responsive

PRINCIPLE (interventions in older people- GP based)

Platform Randomised trial of INterventions against COVID-19 in older peoPLE (PRINCIPLE) trial

The PRINCIPLE trial aims to rapidly evaluate different COVID-19 treatments that could stem the progression of COVID-19 symptoms in older people

Recruitment is via general practice with 9 Liverpool Practices open to recruitment

RECOVERY trial (Evaluation of COVID-19 Therapy)

RECOVERY trial Randomised Evaluation of COVID-19 Therapy

The RECOVERY trial is attempting to identify treatments that might be beneficial for adults who have been hospitalised with COVID-19.

The trial is testing some suggested COVID-19 treatments:

  • Standard of care
  • Lopinavir-Ritonavir (commonly used to treat HIV)
  • Low-dose Dexamethasone (a type of steroid, which is used in a range of conditions typically to reduce inflammation).
  • Hydroxychloroquine (related to an anti-malarial drug)
  • Azithromycin (a commonly used antibiotic)
  • Tocilizumab (an anti-inflammatory treatment given by injection)

The trial has multiple arms and the following LHP sites are open to recruitment:

  • Alder Hey Children’s Hospital
  • Liverpool University Hospitals NHS Foundation Trust
  • Liverpool Womens Hospital
  • The Walton Centre

 

REMAP-CAP (Adaptive Platform trial for Community-Acquired Pneumonia)

Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia 

The REMAP-CAP study aims over time, to determine and continuously update the optimal set of treatments for community-acquired pneumonia. The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by all-cause mortality at 90 days.

The following LHP sites are open to recruitment:

  • Liverpool Heart and Chest Hospital
  • Liverpool University Hospitals NHS Foundation Trust

Further Urgent Public Health (UPH) studies and other COVID-19 research studies are also open across LHP

CCP (Severe Emerging Infection)

ISARIC/WHO Clinical Characterisation Protocol (CCP) for Severe Emerging Infections

The CCP study is designed for the rapid, coordinated clinical investigation of patients with confirmed infection with a pathogen of public interest.

All LHP sites are open to recruitment:

  • Alder Hey Children’s Hospital
  • Clatterbridge Cancer Centre
  • Liverpool Heart and Chest Hospital
  • Liverpool University Hospitals NHS Foundation Trust
  • Liverpool Womens Hospital
  • Merseycare
  • The Walton Centre

 

Coronavirus infection in immunosuppressed children

Coronavirus infection in immunosuppressed children

https://www.hra.nhs.uk/covid-19-research/approved-covid-19-research/281544/

This study is designed to allow families of immunosuppressed children and young people to self-record their experiences of COVID-19 and other viral respiratory illnesses during the COVID-19 epidemic.

The following LHP sites are open to recruitment:

  • Alder Hey Children’s Hospital

DIAMONDS (Diagnosis and Management of Febrile Illness)

Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis

DIAMONDS will develop a new molecular diagnostic test to provide rapid diagnosis of common infectious bacterial disease, as well as viral and inflammatory diseases

The following LHP sites are open to recruitment:

  • Alder Hey Children’s Hospital

 

FASTER (test for Rapid triage)

Facilitating A SARS CoV-2 TEst for Rapid triage

https://www.hra.nhs.uk/covid-19-research/approved-covid-19-research/282147/

The following LHP sites are open to recruitment:

  • Liverpool University Hospitals NHS Foundation Trust

GenOMICC (Genetics of susceptibility & mortality)

Genetics of susceptibility and mortality in critical care

Susceptibility to COVID-19 is almost certainly, in part, genetic. GenOMICC can find the genes that cause susceptibility, which may help us to prioritise treatments to respond to the global crisis. GenOMICC was designed for this crisis. Since 2016, the open, global GenOMICC collaboration has been recruit patients with emerging infections, including COVID-19

The following LHP sites are open to recruitment:

  • Liverpool Heart and Chest Hospital
  • Liverpool University Hospitals NHS Foundation Trust

PRIEST study (Pandemic Respiratory Infection Emergency System Triage)

Pandemic Respiratory Infection Emergency System Triage

The PRIEST study aims to optimise the triage of people using the emergency care system with suspected respiratory infections during a pandemic and to identify the most accurate triage method for predicting severe illness among patients attending the emergency department with suspected respiratory infection

The following LHP sites are open to recruitment:

  • Alder Hey Children’s Hospital
  • Liverpool University Hospitals NHS Foundation Trust

Remdesivir (Evaluation GS-5734)

A Phase 3 Randomised study to evaluate the Safety and Anti-Viral activity of Remdesivir (GS-5734) in participants with severe COVID-19

The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to the normalization of temperature and oxygen saturation through Day 14 in participants with severe coronavirus disease (COVID-19).

The following LHP sites are open to recruitment:

  • Liverpool University Hospitals NHS Foundation Trust

 

 

Remdesivir (Safety & Antiviral Activity 5774)

5774 Safety & Antiviral Activity of Remdesivir for moderate COVID-19

https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials

The following LHP sites are open to recruitment:

  • Liverpool University Hospitals NHS Foundation Trust

 

SAFER (Frontline Health Care Workers)

SARS-CoV-2 Acquisition in Frontline Health Care Workers – Evaluation to Inform Response

The SAFER study will examine rates of SARS-CoV-2 acquisition in health care workers and will assess whether the presence of nasal bacteria (specifically a bacterial called Streptococcus pneumoniae) is associated with increased risk of SARS-CoV-2 infection and Covid-19 disease.

The following LHP sites are open to recruitment:

  • Liverpool University Hospitals NHS Foundation Trust

 

UKOSS (Maternal and Perinatal Outcomes)

Maternal and Perinatal Outcomes of Pandemic Influenza in Pregnancy

The study will use the UK Obstetric Surveillance System (UKOSS) to collect information about all pregnant women admitted to hospital who are confirmed to have the virus infection. It will determine the incidence of pandemic influenza infection in pregnancy

The following LHP sites are open to recruitment:

  • Liverpool Womens Hospital

 

Sign up for our newsletter

If you would like to receive quarterly newsletters from Liverpool Health Partners please sign up here. We won’t use your details for any other purpose, and we won’t pass them on to any other organisation.